Clinical trialPhase 1Unknown
Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SCT200 in Patients With Advanced Solid Tumors
Recombinant Anti-EGFR Monoclonal Antibody(SCT200)in Patients With Advanced Solid Tumors or Lymphoma : A Phase Ⅰb, Open-label, Multicenter Study.
- Outcome
- Outcome unknown
- Phase
- Phase 1
- Status
- Unknown
- Study type
- Interventional
- Start
- 30 September 2018
- Listed end
- 30 April 2020
- Enrollment
- 90 participants
- Sites
- 1
- Primary outcomes
- Objective response rate (ORR)
- Sponsor type
- Industry
- Results posted
- No
- Last update
- 2 October 2018
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The purpose of this study is to evaluate the efficacy and safety of recombinant anti-EGFR monoclonal antibody(SCT200)in patients with advanced solid tumors treated after failure of standard therapy.
Detailed description public domain (ClinicalTrials.gov)
This open label, multicenter phase Ib study is designed to evaluate Objective Response Rate (ORR) in advanced solid tumors (gastric/gastroesophageal junction cancer, hepatocellular carcinoma,pancreatic cancer,gallbladder cancer/bile duct cancer,renal cell carcinoma,ovarian cancer,or other advanced solid tumor) treated with anti-EGFR monoclonal antibody SCT200.